UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Benign Prostatic Hyperplasia
- Lower Urinary Tract Symptoms
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 45 years and 85 years
- Gender
- Only males
Description
The study is a post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard tra...
The study is a post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS). In POST WATER, up to 46 WATER Study subjects in the United Kingdom who were active on the study at 36 months will be invited to participate, across 3 clinical study sites in England and Wales. The study will consist of one follow-up time-point at 60 months (5 years) from the time of initial WATER Study treatment date.
Tracking Information
- NCT #
- NCT04658056
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Claus Roehrborn, MD UT Southwestern Medical Principal Investigator: Peter Gilling, MD Tauranga Urology Research Limited
Get Well Soon